Clinical trials
Ovarian Neoplasms trials in Italy with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 10 |
| Completed | 6 |
| Active, not recruiting | 5 |
| Unknown status | 5 |
| Not yet recruiting | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 13 |
| AGO Study Group | 2 |
| Catholic University of the Sacred Heart | 2 |
| Azienda Ospedaliera di Padova | 1 |
| Azienda Ospedaliero-Universitaria di Parma | 1 |
| Azienda USL 4 Prato | 1 |
| CNAO National Center of Oncological Hadrontherapy | 1 |
| European Institute of Oncology | 1 |
| Gemelli Molise Hospital | 1 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ovarian Neoplasms | 29 |
| Breast Neoplasms | 5 |
| Recurrence | 3 |
| Lung Neoplasms | 2 |
| Melanoma | 2 |
| Urinary Bladder Neoplasms | 2 |
| Adenomyosis | 1 |
| Anemia | 1 |
| Carcinoma | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.